Evolving Cardiac Electrical Therapies for Advanced Heart Failure Patients
Zain I Sharif1, Vincent Galand2,1, William J Hucker1
1Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (Z.I.S., V.G., W.J.H., J.P.S.).
Circulation. Arrhythmia and Electrophysiology
|April 16, 2021
Summary
Managing symptomatic heart failure (HF) is difficult. New electrical therapies, including cardiac contractility modulation and neuromodulation, offer promising options for advanced HF patients not suitable for traditional treatments.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Devices
Background:
- Symptomatic heart failure (HF) management remains challenging despite optimal medical therapy and invasive monitoring.
- Cardiac resynchronization therapy is effective only for a subset of HF patients with wide QRS.
- A significant portion of symptomatic HF patients are not candidates for current advanced therapies.
Purpose of the Study:
- To review emerging electrical therapies for advanced heart failure.
- To examine the role of cardiac contractility modulation, baroreceptor stimulation, and phrenic nerve stimulation.
- To provide a state-of-the-art overview of novel therapeutic options for HF.
Main Methods:
- Literature review of recent advancements in electrical therapies for HF.
- Analysis of FDA-approved devices and emerging therapeutic strategies.
- Examination of the mechanisms and clinical applications of novel electrical interventions.
Main Results:
- Cardiac contractility modulation, carotid baroreceptor stimulation, and phrenic nerve stimulation are emerging as viable therapeutic options.
- These therapies offer new avenues for symptomatic HF patients who are poor candidates for other treatments.
- Recent FDA approvals highlight the growing clinical relevance of these electrical interventions.
Conclusions:
- Evolving electrical therapies represent a significant advancement in managing advanced heart failure.
- These novel approaches hold promise for improving outcomes in a broaderHF patient population.
- Further research and clinical integration of these therapies are warranted.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
75
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
75
01:30Cardiomyopathy II: Dilated Cardiomyopathy
121
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
121
01:29Cardiomyopathy V: Interprofessional Care
104
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
01:30Heart Failure V: Medical Management
68
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
68
01:26Heart Failure Drugs: Inotropic Agents
912
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
912
01:30Heart Failure IV: Classification and Diagnostic Evaluation
111
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
111